Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference
May 02 2022 - 6:30AM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on developing potentially curative therapies
leveraging CRISPR-based technologies, today announced the
presentation of new preclinical data from its differentiated
allogeneic cell engineering platform at Keystone Symposia’s
Precision Genome Engineering Conference, taking place April 27 –
May 1, 2022, in Keystone, Colorado. The data presented support the
development of NTLA-6001, Intellia’s allogeneic CAR-T development
candidate targeting CD30 for the treatment of CD30-expressing
hematologic cancers, including relapsed or refractory classical
Hodgkin lymphoma (cHL).
“We are pleased to present promising preclinical data that led
to the nomination of Intellia’s wholly owned allogeneic development
candidate, NTLA-6001, for CD30-expressing hematologic lymphomas.
NTLA-6001 is the first candidate using our differentiated
allogeneic platform, which leverages a novel combination of
sequential, LNP-delivered gene edits to yield T cells shielded from
immune rejection,” said Intellia Chief Scientific Officer Laura
Sepp-Lorenzino, Ph.D. “Our approach to engineering T cells aims to
solve key immunological challenges to allogeneicity, while
retaining cell attributes necessary for potent and durable tumor
killing. We look forward to advancing NTLA-6001 toward IND-enabling
activities.”
The data shared at Keystone demonstrated that Intellia’s
proprietary allogeneic solution created T cells that not only
avoided immune recognition by host CD4 and CD8 T cells, but also
were protected from NK cell-mediated killing in in vitro and in
vivo mouse models. Furthermore, allogeneic T cells engineered
sequentially with LNPs retained high viability, cell expansion,
memory phenotype, cytotoxic and cytokine secretion characteristics.
Intellia’s allogeneic platform can be deployed for TCR-T and CAR-T
cell therapy.
As part of these platform advancement efforts, Intellia
evaluated multiple CD30 CAR constructs in a series of in vitro and
in vivo experiments. The most potent CAR construct showed complete
tumor regression and protection from tumor rechallenge in a T cell
lymphoma model. This lead allogeneic CAR-T cell candidate,
NTLA-6001, is now in preclinical development for cHL and certain
CD30+ T cell lymphomas. CD30, the target for NTLA-6001, is a cell
surface protein that is often overexpressed in a variety of
hematologic cancers, making it an important candidate for CAR-T
cell therapy.
The presentation is available on Intellia’s website at
www.intelliatx.com.
About Intellia TherapeuticsIntellia
Therapeutics, a leading clinical-stage genome editing company, is
developing novel, potentially curative therapeutics leveraging
CRISPR-based technologies. To fully realize the transformative
potential of CRISPR-based technologies, Intellia is pursuing two
primary approaches. The company’s in vivo programs use
intravenously administered CRISPR as the therapy, in which
proprietary delivery technology enables highly precise editing of
disease-causing genes directly within specific target tissues.
Intellia’s ex vivo programs use CRISPR to create the therapy by
using engineered human cells to treat cancer and autoimmune
diseases. Intellia’s deep scientific, technical and clinical
development experience, along with its robust intellectual property
portfolio, have enabled the company to take a leadership role in
harnessing the full potential of genome editing to create new
classes of genetic medicine. Learn more at intelliatx.com. Follow
us on Twitter @intelliatx.
Forward-Looking Statements This press release
contains “forward-looking statements” of Intellia Therapeutics,
Inc. (“Intellia” or the “Company”) within the meaning of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to, express
or implied statements regarding Intellia’s beliefs and expectations
concerning: its ability to successfully extend its leadership and
harness the full potential of genomic medicines to bolster its
genome editing capabilities and pipeline; its ability to generate
additional data demonstrating the capability of NTLA-6001 to avoid
immune recognition while retaining cell attributes for potent and
durable tumor killing; its ability to deploy its platform
technology, including its allogeneic cell engineering platform, to
develop additional TCR-T and CAR-T cell therapies; its advancement
of its development candidates, including NTLA-6001 for CD30+
lymphomas; its ability to generate data to initiate clinical trials
and the timing of CTA and IND submissions, including for NTLA-6001;
its ability to maintain and expand its related intellectual
property portfolio; and its expectations of the potential impact of
the coronavirus disease 2019 pandemic, including the impact of the
Delta and Omicron variants on strategy, future operations and
timing of its clinical trials, including potential clinical trials
for NTLA-6001.
Any forward-looking statements in this press release are based
on management’s current expectations and beliefs of future events
and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those
set forth in or implied by such forward-looking statements. These
risks and uncertainties include, but are not limited to: risks
related to Intellia’s ability to protect and maintain its
intellectual property position; risks related to Intellia’s
relationship with third parties, including its licensors and
licensees; risks related to the ability of its licensors to protect
and maintain their intellectual property position; uncertainties
related to the authorization, initiation and conduct of studies and
other development requirements for its product candidates,
including uncertainties related to regulatory approvals to conduct
clinical trials; the risk that any one or more of Intellia’s
product candidates will not be successfully developed and
commercialized; the risk that the results of preclinical studies or
clinical studies will not be predictive of future results in
connection with future studies; the risk that clinical study
results will not be positive and the risk that it will not be able
to deploy its allogeneic cell engineering platform to TCR-T and
CAR-T cell therapies. For a discussion of these and other risks and
uncertainties, and other important factors, any of which could
cause Intellia’s actual results to differ from those contained in
the forward-looking statements, see the section entitled “Risk
Factors” in Intellia’s most recent annual report on Form 10-K and
quarterly report on Form 10-Q, as well as discussions of potential
risks, uncertainties, and other important factors in Intellia’s
other filings with the Securities and Exchange Commission (“SEC”).
All information in this press release is as of the date of the
release, and Intellia undertakes no duty to update this information
unless required by law.
Intellia Contacts:
Investors:Ian KarpSenior Vice President,
Investor Relations and Corporate
Communications+1-857-449-4175ian.karp@intelliatx.comLina
LiDirector, Investor Relations and Corporate
Communications+1-857-706-1612lina.li@intelliatx.com
Media:Matt CrensonTen Bridge
Communications+1-917-640-7930media@intelliatx.com
mcrenson@tenbridgecommunications.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jul 2023 to Jul 2024